The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Practice Guidelines for the Management of Cryptococcal Disease
Open accessAbstract
An 8-person subcommittee of the National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group evaluated available data on the treatment of cryptococcal disease. Opinion regarding optimal treatment was based on personal experience and information in the literature. The relative strength of each recommendation was graded according to the type and degree of evidence available to support the recommendation, in keeping with previously published guidelines by the Infectious Diseases Society of America (IDSA). The panel conferred in person (on 2 occasions), by conference call, and through written reviews of each draft of the manuscript. The choice of treatment for disease caused by Cryptococcus neoformans depends on both the anatomic sites of involvement and the host's immune status. For immunocompetent hosts with isolated pulmonary disease, careful observation may be warranted; in the case of symptomatic infection, indicated treatment is fluconazole, 200–400 mg/day for 3–6 months. For those individuals with non-CNS-isolated cryptococcemia, a positive serum cryptococcal antigen titer >1 : 8, or urinary tract or cutaneous disease, recommended treatment is oral azole therapy (fluconazole) for 3–6 months. In each case, careful assessment of the CNS is required to rule out occult meningitis. For those individuals who are unable to tolerate fluconazole, itraconazole (200–400 mg/day for 6–12 months) is an acceptable alternative. For patients with more severe disease, treatment with amphotericin B (0.5–1 mg/kg/d) may be necessary for 6–10 weeks. For otherwise healthy hosts with CNS disease, standard therapy consists of amphotericin B, 0.7–1 mg/kg/d, plus flucytosine, 100 mg/kg/d, for 6–10 weeks. An alternative to this regimen is amphotericin B (0.7–1 mg/kg/d) plus 5-flucytosine (100 mg/kg/d) for 2 weeks, followed by fluconazole (400 mg/day) for a minimum of 10 weeks. Fluconazole “consolidation” therapy may be continued for as along as 6–12 months, depending on the clinical status of the patient. HIV-negative, immunocompromised hosts should be treated in the same fashion as those with CNS disease, regardless of the site of involvement. Cryptococcal disease that develops in patients with HIV infection always warrants therapy. For those patients with HIV who present with isolated pulmonary or urinary tract disease, fluconazole at 200–400 mg/d is indicated. Although the ultimate impact from highly active antiretroviral therapy (HAART) is currently unclear, it is recommended that all HIV-infected individuals continue maintenance therapy for life. Among those individuals who are unable to tolerate fluconazole, itraconazole (200–400 mg/d) is an acceptable alternative. For patients with more severe disease, a combination of fluconazole (400 mg/d) plus flucytosine (100–150 mg/d) may be used for 10 weeks, followed by fluconazole maintenance therapy. Among patients with HIV infection and cryptococcal meningitis, induction therapy with amphotericin B (0.7–1 mg/kg/d) plus flucytosine (100 mg/kg/d for 2 weeks) followed by fluconazole (400 mg/d) for a minimum of 10 weeks is the treatment of choice. After 10 weeks of therapy, the fluconazole dosage may be reduced to 200 mg/d, depending on the patient's clinical status. Fluconazole should be continued for life. An alternative regimen for AIDS-associated cryptococcal meningitis is amphotericin B (0.7–1 mg/kg/d) plus 5-flucytosine (100 mg/kg/d) for 6–10 weeks, followed by fluconazole maintenance therapy. Induction therapy beginning with an azole alone is generally discouraged. Lipid formulations of amphotericin B can be substituted for amphotericin B for patients whose renal function is impaired. Fluconazole (400–800 mg/d) plus flucytosine (100–150 mg/kg/d) for 6 weeks is an alternative to the use of amphotericin B, although toxicity with this regimen is high. In all cases of cryptococcal meningitis, careful attention to the management of intracranial pressure is imperative to assure optimal clinical outcome. As is true for other systemic mycoses, treatment of disease due to C. neoformans have improved dramatically over the last 2 decades. Before 1950, disseminated cryptococcal disease was uniformly fatal. With the advent of polyene antifungal agents, particularly amphotericin B, successful outcomes were achieved in as much as 60%–70% of patients with cryptococcal meningitis, depending on the status of the host at the time of presentation [1]. During the early 1970s, flucytosine was established as an orally bioavailable agent with potent activity against C. neoformans; however, this activity was lost rapidly because of the development of resistance when the drug was used as monotherapy [2]. When flucytosine was added to amphotericin B as combination therapy, overall outcome of therapy was improved and the duration of treatment could be reduced from 10 weeks to 4–6 weeks, depending on the status of the host [1, 3]. Beginning in the 1980s, orally bioavailable azole antifu
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., et al. (1998) · JAMA · doi:10.1001/jama.280.1.78 · Cited by 995
Self-citationBennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H., Leonard, J., Fields, B. T., Bradshaw, M., Haywood, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907193010303 · Cited by 863
Self-citationTreatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707033370103 · Cited by 820
Self-citationInfections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome
Chuck, S. L., & Sande, M. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211205 · Cited by 797
Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, P., Grieco, M. H., Sharkey, P. K., Thompson, S. E., Sugar, A. M., Tuazon, C. U., Fisher, J. F., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260202 · Cited by 631
Self-citationDismukes, W. E., Cloud, G., Gallis, H. A., Kerkering, T. M., Medoff, G., Craven, P. C., Kaplowitz, L. G., Fisher, J. F., Gregg, C. R., Bowles, C. A., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708063170602 · Cited by 417
Self-citationLarsen, R. A., Leal, M. A. E., & Chan, L. S. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-3-183 · Cited by 357
Self-citationPowderly, W. G., Saag, M. S., Cloud, G. A., Robinson, P., Meyer, R. D., Jacobson, J. M., Graybill, J. R., Sugar, A. M., McAuliffe, V. J., Follansbee, S. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261203 · Cited by 353
Self-citation
Cited by
Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu296 · Cited by 2,780
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationPractice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex
Hagen, F., Khayhan, K., Theelen, B., Kolecka, A., Polacheck, I., Sionov, E., Falk, R., Parnmen, S., Lumbsch, H. T., & Boekhout, T. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.02.009 · Cited by 687
The biology and chemistry of antifungal agents: A review
Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S., & Gadhwe, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.045 · Cited by 664
SHELBURNE, S. A., HAMILL, R. J., RODRIGUEZ-BARRADAS, M. C., GREENBERG, S. B., ATMAR, R. L., MUSHER, D. M., GATHE, J. C., VISNEGARWALA, F., & TRAUTNER, B. W. (2002) · Medicine · doi:10.1097/00005792-200205000-00005 · Cited by 654
The contribution of melanin to microbial pathogenesis: Melanin and microbial pathogenesis
Nosanchuk, J. D., & Casadevall, A. (2003) · Cellular Microbiology · doi:10.1046/j.1462-5814.2003.00268.x · Cited by 650
Pappas, P. G., Perfect, J. R., Cloud, G. A., Larsen, R. A., Pankey, G. A., Lancaster, D. J., Henderson, H., Kauffman, C. A., Haas, D. W., Saccente, M., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/322597 · Cited by 642
Self-citationEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Self-citationOpportunistic Infections in Patients with and Patients without Acquired Immunodeficiency Syndrome
Sepkowitz, K. A. (2002) · Clinical Infectious Diseases · doi:10.1086/339548 · Cited by 501
Invasive fungal infections: a review of epidemiology and management options
Enoch, D. A., Ludlam, H. A., & Brown, N. M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46548-0 · Cited by 501
Segal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky‐Zeichner, L., Sobel, J., Viscoli, C., Walsh, T. J., Maertens, J., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 468
Self-citationGalleria mellonella as a Model System To Study Cryptococcus neoformans Pathogenesis
Mylonakis, E., Moreno, R., El Khoury, J. B., Idnurm, A., Heitman, J., Calderwood, S. B., Ausubel, F. M., & Diener, A. (2005) · Infection and Immunity · doi:10.1128/iai.73.7.3842-3850.2005 · Cited by 433
Baker, L. G., Specht, C. A., Donlin, M. J., & Lodge, J. K. (2007) · Eukaryotic Cell · doi:10.1128/ec.00399-06 · Cited by 379
Chayakulkeeree, M., & Perfect, J. R. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.001 · Cited by 378
Self-citationDeterminants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
Dromer, F., Mathoulin-Pélissier, S., Launay, O., Lortholary, O., & the French Cryptococcosis Study Group (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040021 · Cited by 374
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
Perfect, J. R., & Casadevall, A. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00036-3 · Cited by 363
Self-citationBicanic, T., & Harrison, T. S. (2004) · British Medical Bulletin · doi:10.1093/bmb/ldh043 · Cited by 361
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Moen, M. D., Lyseng-Williamson, K. A., & Scott, L. J. (2009) · Drugs · doi:10.2165/00003495-200969030-00010 · Cited by 321
Therapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 313
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug
Mesa-Arango, A. C., Scorzoni, L., & Zaragoza, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00286 · Cited by 311
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Haddow, L. J., Colebunders, R., Meintjes, G., Lawn, S. D., Elliott, J. H., Manabe, Y. C., Bohjanen, P. R., Sungkanuparph, S., Easterbrook, P. J., French, M. A., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70170-5 · Cited by 302
Kambugu, A., Meya, D. B., Rhein, J., O’Brien, M., Janoff, E. N., Ronald, A. R., Kamya, M. R., Mayanja‐Kizza, H., Sande, M. A., Bohjanen, P. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587667 · Cited by 300
Bicanic, T., Meintjes, G., Wood, R., Hayes, M., Rebe, K., Bekker, L.-G., & Harrison, T. (2007) · Clinical Infectious Diseases · doi:10.1086/518607 · Cited by 271
Immune defence to invasive fungal infections: A comprehensive review
Pathakumari, B., Liang, G., & Liu, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110550 · Cited by 264
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
HIV-associated cryptococcal meningitis
Jarvis, J. N., & Harrison, T. S. (2007) · AIDS · doi:10.1097/qad.0b013e3282a4a64d · Cited by 252
Mesa-Arango, A. C., Trevijano-Contador, N., Román, E., Sánchez-Fresneda, R., Casas, C., Herrero, E., Argüelles, J. C., Pla, J., Cuenca-Estrella, M., & Zaragoza, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03570-14 · Cited by 232
Recombinant Interferon‐γ1b as Adjunctive Therapy for AIDS‐Related Acute Cryptococcal Meningitis
Pappas, P. G., Bustamante, B., Ticona, E., Hamill, R. J., Johnson, P. C., Reboli, A., Aberg, J., Hasbun, R., & Hsu, H. H. (2004) · The Journal of Infectious Diseases · doi:10.1086/420829 · Cited by 202
Self-citationWormley, F. L., Perfect, J. R., Steele, C., & Cox, G. M. (2007) · Infection and Immunity · doi:10.1128/iai.00274-06 · Cited by 187
Self-citationMaligie, M. A., & Selitrennikoff, C. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2851-2856.2005 · Cited by 178
Posteraro, B., Sanguinetti, M., Sanglard, D., La Sorda, M., Boccia, S., Romano, L., Morace, G., & Fadda, G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03281.x · Cited by 143
Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans
Waterman, S. R., Hacham, M., Hu, G., Zhu, X., Park, Y.-D., Shin, S., Panepinto, J., Valyi-Nagy, T., Beam, C., Husain, S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30006 · Cited by 134
Infections of the nervous system
Parikh, V., Tucci, V., & Galwankar, S. (2012) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.97273 · Cited by 106
Billmyre, R. B., Applen Clancey, S., Li, L. X., Doering, T. L., & Heitman, J. (2020) · Nature Communications · doi:10.1038/s41467-019-13890-z · Cited by 102
Management of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100
Protective Immunity against Experimental Pulmonary Cryptococcosis in T Cell-Depleted Mice
Wozniak, K. L., Young, M. L., & Wormley, F. L. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00036-11 · Cited by 72
Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis
Lu, R., Hollingsworth, C., Qiu, J., Wang, A., Hughes, E., Xin, X., Konrath, K. M., Elsegeiny, W., Park, Y.-D., Atakulu, L., et al. (2019) · mBio · doi:10.1128/mbio.00724-19 · Cited by 67
Gusa, A., Williams, J. D., Cho, J.-E., Averette, A. F., Sun, S., Shouse, E. M., Heitman, J., Alspaugh, J. A., & Jinks-Robertson, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001451117 · Cited by 65
A Call to Arms: Quest for a Cryptococcal Vaccine
Caballero Van Dyke, M. C., & Wormley, F. L. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.002 · Cited by 61
Fungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.013 · Cited by 33
Cryptococcal Choroid Plexitis an Uncommon Fungal Disease. Case Report and Review
Graciela Agar, C. H., Rosalba, V. O., Ivan, C. M., Agnes, F., Juan Luis, G. A., & José Luis, S. H. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100006454 · Cited by 12
Metadata
- Authors
- Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E., & Mycoses Study Group Cryptococcal Subproject
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 30
- Issue
- 4
- Pages
- 710-718
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2104376815
- Cited by
- 1,105
- References
- 34
- FWCI
- 30.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.